Ultralow Dose Thoracic Computed Tomography in Immunocompromised Patients — ULDCT-IC  

Leukemia Clinical Trial

Official title: Ultralow Dose Thoracic Computed Tomography in Immunocompromised Patients

Status Terminated

Clinical Trial Summary

Patients with bone marrow cancer are more susceptible to chest infections than healthy adults; marrow ablation treatment further compromises their immune status and increases the risk of fungal opportunistic infection, which is associated with a high fatality rate. Therefore, it is critical to achieve early and accurate diagnosis of fungal infection when these patients become febrile. At the Mount Sinai Hospital (MSH) and the University Health Network (UHN), the standard of care (SOC) to exclude a chest infection in immunocompromised (IC) patients is chest computed tomography (CT) using low dose CT (LDCTT).

Clinical Trial Description

As patients may have several febrile episodes during their hospital stay, the cumulative dose from LDCTT scans can be significant and increase the lifetime risk of inducing a second cancer. The aim of this project is to determine whether a 75% reduction in radiation dose for LDCTT in other words, an ultralow dose chest CT (uLDCTT) at a dose comparable to chest X-ray, maintains the diagnostic image quality for detection of fungal chest infection in IC patients. If successful, uLDCTT will be adopted as SOC imaging at Princess Margaret Cancer Center (PM) for these patients. ;

Related Conditions & MeSH terms

• Leukemia

• NCT number: NCT02755480
• Study type: Interventional
• Source: University Health Network, Toronto
• Status: Terminated
• Phase: N/A
• Start date: February 2015
• Completion date: February 2017